Our group is dedicated to democratizing retinal gene therapy by developing precise, cost-effective interventions for inherited and chronic eye diseases. We leverage in vitro-transcribed mRNA and innovative biomaterial-based delivery systems to overcome the limitations of traditional viral therapies. Our goal is to transform eye care and make advanced genetic therapies accessible to patients worldwide.